openPR Logo
Press release

Long Island Resident Karen Henley Receives 2011 Advocate of the Year Award

03-17-2011 11:59 AM CET | Associations & Organizations

Press release from: Alzheimer’s Association Long Island

/ PR Agency: PRMG
Ronkonkoma, March 2, 2011 – “There is no one more worthy of this award than Karen Henley,” states Mary Ann Malack-Ragona, CEO for the Long Island Chapter of the Alzheimer’s Association. “Karen has put a face on Young Onset Alzheimer’s Disease and is leading the way for change.” On March 2nd, 2011, the Coalition of New York State Alzheimer’s Association Chapters, Inc. will present Mrs. Henley with the 2011 Frank Carlino Outstanding Advocate Award in recognition of exemplary service to the Alzheimer’s community and for her public policy efforts on behalf of all Long Island families who are coping with the challenges of Alzheimer’s Disease.

Mrs. Henley is being recognized for her Public Policy efforts in Washington, DC during 2010 — efforts that helped the Alzheimer’s Association pass the National Project Act (NAPA), a legislative initiative that will create a coordinated national plan to overcome the Alzheimer crisis and will ensure the coordination and evaluation of all national efforts in Alzheimer’s research, clinical care, institutional, and home and community-based programs and their outcomes. President Barack Obama signed NAPA into law on January 4th, 2011.

Mrs. Henley’s husband, Mike, was diagnosed with Young Onset Alzheimer’s Disease in 2001 at the age of thirty-seven. Mrs. Henley has become a spokesperson for all individuals in this country who have a diagnosis of Young Onset Alzheimer’s Disease, appearing on local TV, sharing her story with Newsday and speaking at the Chapter’s Annual Education Conference. The family also raises money every year for the Chapter’s Annual Walk To End Alzheimer’s helping to support the full Mission of the Association – Research, Care and Cure.

Currently 5.3 million people in this country have Alzheimer’s Disease and more than 200,000 individuals under the age of 65 have a diagnosis of AD. By the middle of this century, it is estimated that approximately 14-16 million people will have a diagnosis of Alzheimer’s Disease; one out of eight baby boomers is at risk. The annual cost of Alzheimer’s disease will soar to at least $375 billion, overwhelming our health care system and bankrupting Medicare and Medicaid. Alzheimer’s disease does not happen overnight; it begins to attack the brain of its potential victims 10 to 20 years before the first symptoms appear. To protect today’s baby boomers from the ravages of Alzheimer’s Disease, we have to find ways to stop this disease process now, while there is still time to prevent the damage.

The Alzheimer’s Association is the nation’s leading voluntary health organization dedicated to supporting families and caregivers by providing vital programs and services in local communities nationwide. The Association is the largest private funder of Alzheimer’s research, having committed more than $200 million to research. A minimum of 75% of every dollar raised by the Alzheimer’s Association funds programs to promote research, find effective treatments, and improve the lives of those affected by Alzheimer’s.

For more information about the Alzheimer’s Association, please contact Mary Ann Malack-Ragona, Executive Director/CEO at (631) 820-8068 or visit us at www.alz.org/longisland.

Hank Russell, Public Relations Director
PRMG
156 North Ocean Avenue
Patchogue, NY 11772
631-207-1057
hrussell@theprmg.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Long Island Resident Karen Henley Receives 2011 Advocate of the Year Award here

News-ID: 166878 • Views:

More Releases from Alzheimer’s Association Long Island

Sunrise Senior Living Bowls for a Cause to Benefit Alzheimer’s Association Lon …
Sunrise Senior Living in West Babylon is spearheading a bowling event for the rest of the Sunrise communities that will take place November 3 at 300 Long Island, 895 Walt Whitman Road in Melville, from 1-3 p.m. The event will raise money for Alzheimer’s Association Long Island. The cost is $25 per person, which includes shoe rental, a slice of pizza, soda and two hours of bowling. All proceeds will be
Alzheimer’s Association Long Island and NYC Chapters Present Public Input Sess …
On August 18, the Alzheimer’s Association Long Island Chapter will join the New York City chapter in holding a public input session to solicit views, comments and perspectives from stakeholders in the Alzheimer’s community to assist with the development of a successful National Alzheimer’s Plan. The recommendations and comments expressed during these input sessions, taking place across the country in August, will be collected and shared this fall with officials
Last Chance for Walkers to Register for 2011 Walk to End Alzheimer’s
Alzheimer’s Association Long Island is reminding all walkers to register for the2011 Walk to End Alzheimer’s/Oktoberfest, if they have not already done so. The walk will take place September 10 at Old Bethpage Village Restoration, 1303 Round Swamp Road, Old Bethpage. This is a 5-kilometer (3.1-mile) walk and will be held rain or shine. Although participants can register individually, team registration is crucial for the organization to reach its goal this
Bankers Conseco Life Insurance Company Presents 9th Annual Forget Me Not Days Fu …
Ronkonkoma, NY — Alzheimer’s Association Long Island has announced that Bankers Conseco Life Insurance Company is hosting its Ninth Annual Forget Me Not Days fundraiser, which will be taking place May 13-14. Employees from Bankers Conseco’s Islandia branch will be wearing distinctive green aprons and collecting donations for Alzheimer’s Association Long Island at three separate locations: ● Ace Hardware, 3606 Veterans Highway, Bohemia (May 13-14, 9 a.m.-4 p.m.) ● Waldbaum’s, 4054 Nesconset

All 5 Releases


More Releases for Alzheimer

Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is
Anti-β-Alzheimer Therapies Market : Consumption, Revenue, Applications With Maj …
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer
Anti-β-Alzheimer Therapies That Cut Attacks Hailed As 'huge Deal'
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer
Alzheimer Diagnostic Tests Market - Medical Devices Pipeline Assessment, 2017 | …
"The Latest Research Report Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Alzheimer Diagnostic Tests Market GlobalData's Medical Devices sector report, Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Alzheimer Diagnostic Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports. Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as